GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (STU:AT2) » Definitions » Quick Ratio

Atara Biotherapeutics (STU:AT2) Quick Ratio : 0.65 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Atara Biotherapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Atara Biotherapeutics's quick ratio for the quarter that ended in Dec. 2023 was 0.65.

Atara Biotherapeutics has a quick ratio of 0.65. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Atara Biotherapeutics's Quick Ratio or its related term are showing as below:

STU:AT2' s Quick Ratio Range Over the Past 10 Years
Min: 0.65   Med: 6.87   Max: 38.92
Current: 0.65

During the past 12 years, Atara Biotherapeutics's highest Quick Ratio was 38.92. The lowest was 0.65. And the median was 6.87.

STU:AT2's Quick Ratio is ranked worse than
86.74% of 1553 companies
in the Biotechnology industry
Industry Median: 3.49 vs STU:AT2: 0.65

Atara Biotherapeutics Quick Ratio Historical Data

The historical data trend for Atara Biotherapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Quick Ratio Chart

Atara Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.43 6.31 3.64 3.72 0.65

Atara Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.72 3.22 2.21 1.42 0.65

Competitive Comparison of Atara Biotherapeutics's Quick Ratio

For the Biotechnology subindustry, Atara Biotherapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Quick Ratio falls into.



Atara Biotherapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Atara Biotherapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(93.414-8.9)/130.421
=0.65

Atara Biotherapeutics's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(93.414-8.9)/130.421
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atara Biotherapeutics  (STU:AT2) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Atara Biotherapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics (STU:AT2) Business Description

Traded in Other Exchanges
Address
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics (STU:AT2) Headlines

No Headlines